NCT02467790 is a Phase 1 clinical trial of PEX168 in Type 2 Diabetes Mellitus, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd..

Who is sponsoring NCT02467790?

NCT02467790 is sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd..

What drugs are being tested in NCT02467790?

Interventions in NCT02467790: PEX168.

What condition does NCT02467790 study?

NCT02467790 studies Type 2 Diabetes Mellitus.

Is NCT02467790 still recruiting?

NCT02467790 is currently status unknown. Last updated 23 January 2016.

Last reviewed 2016-01-23 · How we verify

NCT02467790

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Kinetic Study of Human Pharmacokinetics in Normal Renal Function, and Renal Insufficiency Subject of Polyethylene Glycol Loxenatide (PEX168)(Open, Non-randomized, Parallel-group)

Status unknown Phase 1 Last updated 23 January 2016

What this trial tests

Phase 1 trial testing PEX168 in Type 2 Diabetes Mellitus in 24 participants. Status unknown.

Timeline

1 February 2015

Primary endpoint
1 March 2016

1 May 2016

Quick facts

Lead sponsor	Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	1 February 2015
Primary completion	1 March 2016
Estimated completion	1 May 2016
Sites	1 location across China

Drugs / interventions tested

PEX168 — full drug profile →

Conditions studied

Type 2 Diabetes Mellitus — all drugs for Type 2 Diabetes Mellitus →

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd. — full company profile →

Who can join

Adults 31 to 65, any sex, with Type 2 Diabetes Mellitus. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Pharmacokinetic index
Time frame: Baseline to Day31
Prior to administration (within 60 minutes, recorded as 0h) and after administration 24h (Day 2), 48h (Day 3), 72h (day 4), 96h (day 5), 120h (day 6 ), 144h (day 7), 216h (day 10), 312h (day 14 ), 480h (day 21), 648h (day 28), 720h (day 31) collect blood 3 ml and test serum concentrations of PEX168.

Sponsor's own description

To compare and analysis pharmacokinetics of PEX 168 in patients with renal insufficiency or normal renal function who were administrated subcutaneously single dose PEX168.To evaluate dose adjustment of PEX168 administered in patients with renal insufficiency and provide a scientific basis in patients with renal insufficiency of rational drug use.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Polyethylene glycol loxenatide (PEX168) in subjects with renal impairment: A pharmacokinetic study.
Wang J, Huang J, Li W, Tang S, et al · · 2019 · cited 14× · PMID 31396983 · DOI 10.1111/bcp.14091
Research Progress on Peptide Drugs for Type 2 Diabetes and the Possibility of Oral Administration.
Yang X, Lin R, Feng C, Kang Q, et al · · 2024 · cited 2× · PMID 39598478 · DOI 10.3390/pharmaceutics16111353

Verify or expand the search:

Other trials of PEX168

Trials testing the same drug.

NCT02461914 — Evaluate the Pharmacokinetics of Warfarin When Coadministered With PEX168 in Healthy Adult Subjects · Phase 1 · completed
NCT02472236 — Evaluate the Pharmacokinetics of Digoxin When Coadministered With PEX168 in Healthy Adult Subjects · Phase 1 · completed
NCT02447601 — Evaluate the Pharmacokinetics of Simvastatin When Coadministered With PEX168 in Healthy Adult Subjects · Phase 1 · completed

Other recruiting trials for Type 2 Diabetes Mellitus

Currently open trials in the same condition.

NCT07351058 — A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes · Phase 3 · recruiting
NCT07373938 — Carotid Wall Texture as a Cardiovascular Risk Biomarker in Type 2 Diabetes Mellitus · recruiting
NCT07433062 — A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With · Phase 1 · recruiting
NCT07276776 — An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes · NA · active not recruiting
NCT07232537 — An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic · recruiting

Other Jiangsu Hansoh Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT07468851 — A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radic · Phase 1, PHASE2 · not yet recruiting
NCT07483437 — A Study of HS-20136-2 in Healthy Participants · Phase 1 · not yet recruiting
NCT07535970 — A Phase I Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HS-10506 in Healthy Chinese Adult Part · Phase 1 · not yet recruiting
NCT07503015 — Phase 1 Study of HS-20152 in Healthy Participants · Phase 1 · not yet recruiting
NCT07414953 — A Phase Ib Study of HS-10504 Combined Therapy in NSCLC · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02467790 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jiangsu Hansoh Pharmaceutical Co., Ltd.
Last refreshed: 23 January 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02467790.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing